首页 › 基金 › Avidity Partners Management LP › VIR
Avidity Partners Management LP 对 VIR 的持仓历史
VIR BIOTECHNOLOGY INC · 医疗保健
Avidity Partners Management LP 在 Q2 2026 的 13F 申报中披露持有 VIR(VIR BIOTECHNOLOGY INC)519,300 股,市值约 US$5.3M,约占其申报组合的 0.85%,在其申报持仓中市值排名第 18 位。 Avidity Partners Management LP 最近 2 个申报季度中有 2 个季度披露了 VIR 持仓,最早可追溯至 Q1 2026。
最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR
Avidity Partners Management LP 对 VIR 的持仓演变
Avidity Partners Management LP 于 Q1 2026 首次披露 VIR 持仓:950,000 股(约 US$8.5M)。 在 2 次申报中,Avidity Partners Management LP 0 次增持、1 次减持、0 次保持不变。 最近一期申报(Q2 2026)显示持股 519,300 股、市值约 US$5.3M,环比减持 -430,700 股。。 持仓曾出现大幅变动:Q2 2026 减持约 45% (随后一个季度股价上涨 10%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q1 2026 | 950.00K | $8.51M | 新进 |
| Q2 2026 | 519.30K | $5.29M | 减持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 VIR 与 13F 数据
VIR(VIR BIOTECHNOLOGY INC)属于医疗保健行业。我们追踪的基金中还有 49 只申报持有 VIR,申报仓位最大的包括:ARCH Venture Management, LLC (US$129.4M), SB INVESTMENT ADVISERS (UK) LTD (US$111.6M), GSK plc (US$87.1M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 VIR 的基金
- ARCH Venture Management, LLC 12.69M 股 · $129.35M · Q2 2026
- SB INVESTMENT ADVISERS (UK) LTD 10.95M 股 · $111.56M · Q2 2026
- GSK plc 8.55M 股 · $87.13M · Q2 2026
- ADAR1 Capital Management, LLC 2.46M 股 · $25.03M · Q2 2026
- Boxer Capital Management, LLC 1.87M 股 · $19.01M · Q2 2026
- GordonMD Global Investments LP 1.35M 股 · $13.79M · Q2 2026
- Sio Capital Management, LLC 1.08M 股 · $10.96M · Q2 2026
- SUPERSTRING CAPITAL MANAGEMENT LP 853.68K 股 · $8.70M · Q2 2026
- Saturn V Capital Management LP 770.64K 股 · $7.85M · Q2 2026
- Jones Hill Capital LP 659.21K 股 · $6.72M · Q2 2026
- Alta Partners Management Company, L.P. 509.92K 股 · $5.20M · Q2 2026
更多关于 Avidity Partners Management LP
常见问题
How long has Avidity Partners Management LP held VIR?
Avidity Partners Management LP has disclosed VIR holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Avidity Partners Management LP's current position in VIR?
As of Q2 2026, Avidity Partners Management LP holds 519.30K shares of VIR (VIR BIOTECHNOLOGY INC), valued at $5.29M, representing 0.85% of its reported portfolio and ranking #18.
Has Avidity Partners Management LP been buying or selling VIR?
In the latest 13F filing (Q2 2026), Avidity Partners Management LP reduced its position in VIR.
Which other funds hold VIR?
Other major institutional holders of VIR include ARCH Venture Management, LLC, SB INVESTMENT ADVISERS (UK) LTD, GSK plc, among 49 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.